Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Clinical Outcome of Chemoradiation Therapy in Patients with Limited-Disease Small Cell Lung Cancer with Ipsilateral Pleural Effusion

Clinical Outcome of Chemoradiation Therapy in Patients with Limited-Disease Small Cell Lung... ORIGINAL ARTICLE Clinical Outcome of Chemoradiation Therapy in Patients with Limited-Disease Small Cell Lung Cancer with Ipsilateral Pleural Effusion Seiji Niho, MD,* Kaoru Kubota, MD,* Kiyotaka Yoh, MD,* Koichi Goto, MD,* Hironobu Ohmatsu, MD,* Keiji Nihei, MD,† Nagahiro Saijo, MD,* and Yutaka Nishiwaki, MD* Key Words: Small cell lung cancer, Limited-disease, Pleural effu- Background: The indications for definitive thoracic radiotherapy sion, Chemoradiation. (TRT) in limited-disease small cell lung cancer (LD-SCLC) and (J Thorac Oncol. 2008;3: 723–727) ipsilateral pleural effusion have not been thoroughly investigated. We retrospectively investigated the clinical outcome of LD-SCLC patients with ipsilateral pleural effusion. ung cancer is the leading cause of cancer-related deaths Methods: The medical records of SCLC patients who received Lworldwide. In Japan, over 56,000 people died of lung cancer treatment at the National Cancer Center Hospital East between July in 2003. Small cell lung cancer (SCLC) accounts for about 15% 1992 and December 2006 were reviewed. Sixty-three of the 373 of all forms of lung cancer. SCLC has a more aggressive LD-SCLC patients (17%) had ipsilateral pleural effusion. Of these, biologic behavior than non-small cell lung cancer. At the time of 62 patients received chemotherapy as an initial treatment, and were presentation, two-thirds http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Clinical Outcome of Chemoradiation Therapy in Patients with Limited-Disease Small Cell Lung Cancer with Ipsilateral Pleural Effusion

Nishiwaki, Yutaka
Journal of Thoracic Oncology , Volume 3 (7) – Jul 1, 2008
Download PDF
5 pages

Loading next page...
 
/lp/wolters-kluwer-health/clinical-outcome-of-chemoradiation-therapy-in-patients-with-limited-nwOGZSeDre

References (14)

ISSN
1556-0864
DOI
10.1097/JTO.0b013e31817c606a
pmid
18594317
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE Clinical Outcome of Chemoradiation Therapy in Patients with Limited-Disease Small Cell Lung Cancer with Ipsilateral Pleural Effusion Seiji Niho, MD,* Kaoru Kubota, MD,* Kiyotaka Yoh, MD,* Koichi Goto, MD,* Hironobu Ohmatsu, MD,* Keiji Nihei, MD,† Nagahiro Saijo, MD,* and Yutaka Nishiwaki, MD* Key Words: Small cell lung cancer, Limited-disease, Pleural effu- Background: The indications for definitive thoracic radiotherapy sion, Chemoradiation. (TRT) in limited-disease small cell lung cancer (LD-SCLC) and (J Thorac Oncol. 2008;3: 723–727) ipsilateral pleural effusion have not been thoroughly investigated. We retrospectively investigated the clinical outcome of LD-SCLC patients with ipsilateral pleural effusion. ung cancer is the leading cause of cancer-related deaths Methods: The medical records of SCLC patients who received Lworldwide. In Japan, over 56,000 people died of lung cancer treatment at the National Cancer Center Hospital East between July in 2003. Small cell lung cancer (SCLC) accounts for about 15% 1992 and December 2006 were reviewed. Sixty-three of the 373 of all forms of lung cancer. SCLC has a more aggressive LD-SCLC patients (17%) had ipsilateral pleural effusion. Of these, biologic behavior than non-small cell lung cancer. At the time of 62 patients received chemotherapy as an initial treatment, and were presentation, two-thirds

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Jul 1, 2008

There are no references for this article.